Loading organizations...
Key people at assisi animal health.
Assisi Animal Health is a Santa Fe, New Mexico-based veterinary therapeutics company that develops and distributes non-invasive, wearable medical devices for companion animals. The organization utilizes targeted pulsed electromagnetic field technology in its flagship Assisi Loop and Calmer Canine products to treat pain, inflammation, and behavioral disorders without the use of pharmaceuticals. Operating with fewer than 25 employees and generating under $5 million in standalone annual revenue, the company has successfully treated more than 100,000 pets and collaborated with over 40 key veterinary opinion leaders worldwide. In July 2021, the business was acquired by publicly traded veterinary health firm Zomedica, which reported $25.2 million in 2023 revenue, integrating its product lines under the leadership of executives including Francis Russo, Marina Woollen, and Zomedica chief executive officer Larry Heaton. Assisi Animal Health was originally founded in 2010.
Key people at assisi animal health.
Assisi Animal Health is a veterinary medical-device company that develops and sells targeted pulsed electromagnetic field (tPEMF) therapy devices for pets—products designed to reduce pain and inflammation, accelerate healing, and manage anxiety in companion animals[4]. [1]
High-Level Overview
Assisi Animal Health is a product company whose mission is to provide non‑pharmaceutical, science‑based therapeutic options that empower veterinarians and pet owners to improve animal recovery and comfort; the company markets tPEMF devices for treating pain, inflammation, wounds, and anxiety in dogs and other pets[2][4]. Assisi’s product family includes clinical devices such as the Assisi Loop (for inflammation and pain) and Calmer Canine (an over‑the‑counter anxiety treatment system), sold through veterinary clinics and an online store for pet parents and professionals[1][4]. The company positions itself at the intersection of veterinary care and home/clinic wearable therapy, aiming to augment or reduce reliance on drugs and speed recovery for common veterinary conditions[4].
Origin Story
Assisi’s public materials describe a vision of “empowering pets, veterinarians, and owners” and positioning tPEMF as an innovative option in veterinary medicine; the company grew around commercializing tPEMF technology for companion animals[2]. Assisi has collaborated with partners and distributors and expanded its product line and retail partnerships (for example, product launches and collaborations reported around 2018–2019) while operating from Santa Fe, New Mexico[1][4]. Early milestones reported in press releases include the launch of the Calmer Canine anxiety system and product collaborations such as the Assisi Loop Lounge bed introduced with Sleepypod to offer broader therapeutic coverage[1][4].
Core Differentiators
Role in the Broader Tech and Veterinary Landscape
Assisi rides the broader trends toward non‑drug, device‑based therapies, wearable and home‑use medical devices, and a growing focus on improving companion‑animal quality of life through evidence‑based adjunctive therapies[4]. The timing aligns with increasing pet healthcare spending, greater owner willingness to pursue advanced therapies, and interest among veterinarians in multimodal pain management that reduces opioid/NSAID reliance[4]. By commercializing a non‑invasive modality with both clinical and consumer channels, Assisi influences adoption patterns for adjunctive therapies and helps normalize at‑home therapeutic devices in veterinary care[2][4].
Quick Take & Future Outlook
Assisi’s next phase likely centers on expanding clinical evidence, broader veterinary adoption, international distribution, and potentially more product variations or integrations with clinic care pathways—moves that would deepen its influence in multimodal veterinary therapy[4]. Key trends that will shape its journey include demand for non‑pharmaceutical pain and anxiety treatments, reimbursement or clinic purchasing practices, and the strength of clinical outcomes data that veterinarians use to adopt new devices[4][2]. If Assisi continues to build peer‑reviewed evidence and scale its veterinary channel, it could become a go‑to tPEMF provider in companion animal care; conversely, wider uptake will depend on demonstrated cost‑effectiveness versus alternative therapies and regulatory/market acceptance[4].
If you’d like, I can:
Sources: Assisi company site and product pages[4]; industry/company summaries and press reports[1][2].
